Open-label pilot RCT in 30 adults with active ulcerative colitis: colonic FMT gave a higher week-8 clinical response than nasogastric FMT in the per-protocol analysis (9/12, 75% vs 2/8, 25%; risk ratio 2.94, 95% CI 0.84–10.30). Response tracked microbial engraftment.
RCTn = 30
Quraishi et al. Mechanistic insights into fecal microbiota transplantation for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial